Literature DB >> 18681822

An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population.

Donna Jo Smith1, Sabina Wakasiaka, Tina Dan My Hoang, Job Joab Bwayo, Carlos Del Rio, Frances H Priddy.   

Abstract

PURPOSE: We sought to assess the potential acceptability of intravaginal rings (IVRs) as an HIV prevention method among at-risk women and men.
METHODS: We conducted a qualitative assessment of initial attitudes toward IVRs, current HIV prevention methods, and common behavioral practices among female sex workers (FSWs) and men who frequent FSWs in Mukuru, an urban slum community in Nairobi, Kenya. Nineteen women and 21 men took part in six focus group discussions.
RESULTS: Most participants, both male and female, responded positively to the concept of an IVR as a device for delivering microbicides. Women particularly liked the convenience offered by its slow-release capacity. Some female respondents raised concerns about whether male customers would discover the ring and respond negatively, whereas others thought it unlikely that their clients would feel the ring. Focus groups conducted with male clients of FSWs suggested that many would be enthusiastic about women, and particularly sex workers, using a microbicide ring, but that women's fears about negative responses to covert use were well founded. Overall, this high-risk population of FSWs and male clients in Nairobi was very open to the IVR as a potential HIV prevention device.
CONCLUSION: Themes that emerged from the focus groups highlight the importance of understanding attitudes toward IVRs as well as cultural practices that may impact IVR use in high-risk populations when pursuing clinical development of this potential HIV prevention device.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18681822      PMCID: PMC2942749          DOI: 10.1089/jwh.2007.0529

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  17 in total

Review 1.  Assessing the role of anal intercourse in the epidemiology of AIDS in Africa.

Authors:  Stuart Brody; John J Potterat
Journal:  Int J STD AIDS       Date:  2003-07       Impact factor: 1.359

Review 2.  Covert use of topical microbicides: implications for acceptability and use.

Authors:  Cynthia Woodsong
Journal:  Int Fam Plan Perspect       Date:  2004-06

3.  Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya.

Authors:  M Schwandt; C Morris; A Ferguson; E Ngugi; S Moses
Journal:  Sex Transm Infect       Date:  2006-06-21       Impact factor: 3.519

4.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

5.  Intravaginal practices, vaginal flora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women.

Authors:  J H van De Wijgert; P R Mason; L Gwanzura; M T Mbizvo; Z M Chirenje; V Iliff; S Shiboski; N S Padian
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability.

Authors:  A Novák; C de la Loge; L Abetz; E A van der Meulen
Journal:  Contraception       Date:  2003-03       Impact factor: 3.375

7.  Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms.

Authors:  Leon Speroff
Journal:  Obstet Gynecol       Date:  2003-10       Impact factor: 7.661

8.  Acceptability of a microbicide among women and their partners in a 4-country phase I trial.

Authors:  Margaret E Bentley; Andrew M Fullem; Elizabeth E Tolley; Clifton W Kelly; Neelam Jogelkar; Namtip Srirak; Liness Mwafulirwa; Gertrude Khumalo-Sakutukwa; David D Celentano
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

9.  Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings.

Authors:  Karl Malcolm; David Woolfson; Julie Russell; Paul Tallon; Liam McAuley; Duncan Craig
Journal:  J Control Release       Date:  2003-06-24       Impact factor: 9.776

10.  'Dry sex' and HIV infection among women attending a sexually transmitted diseases clinic in Lusaka, Zambia.

Authors:  L Sandala; P Lurie; M R Sunkutu; E M Chani; E S Hudes; N Hearst
Journal:  AIDS       Date:  1995-07       Impact factor: 4.177

View more
  20 in total

Review 1.  Microbicides: topical prevention against HIV.

Authors:  Robin J Shattock; Zeda Rosenberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 2.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

3.  Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.

Authors:  E Pleasants; T Tauya; K Reddy; B G Mirembe; K Woeber; T Palanee-Phillips; C Zimba; M Atujuna; E T Montgomery
Journal:  AIDS Behav       Date:  2020-03

4.  A Qualitative Systematic Review of Women's Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies.

Authors:  Sara E Vargas; Miriam M Midoun; Melissa Guillen; Melissa L Getz; Kristen Underhill; Caroline Kuo; Kate M Guthrie
Journal:  Perspect Sex Reprod Health       Date:  2019-05-20

5.  MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.

Authors:  Louise A Ouattara; Patrick Barnable; Paul Mawson; Samantha Seidor; Thomas M Zydowsky; Larisa Kizima; Aixa Rodriguez; José A Fernández-Romero; Michael L Cooney; Kevin D Roberts; Agegnehu Gettie; James Blanchard; Melissa Robbiani; Natalia Teleshova
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release.

Authors:  Ryan S Teller; David C Malaspina; Rachna Rastogi; Justin T Clark; Igal Szleifer; Patrick F Kiser
Journal:  J Control Release       Date:  2015-12-23       Impact factor: 9.776

7.  Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Etana Kopin; Cali Nguyen; Josh Gilman; Irina Butkyavichene; Kathleen L Vincent; Massoud Motamedi; David R Friend; Meredith R Clark; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

8.  Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.

Authors:  Pedro M M Mesquita; Rachna Rastogi; Theodore J Segarra; Ryan S Teller; N Merna Torres; Ashley M Huber; Patrick F Kiser; Betsy C Herold
Journal:  J Antimicrob Chemother       Date:  2012-03-30       Impact factor: 5.790

9.  Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Irina Butkyavichene; Cassandra Cortez; Joshua Gilman; Sean Kennedy; Etana Kopin; Cali Nguyen; Preetha Sinha; R Michael Hendry; Patricia Guenthner; Angela Holder; Amy Martin; Janet McNicholl; James Mitchell; Chou-Pong Pau; Priya Srinivasan; James M Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

10.  A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.

Authors:  Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.